HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients

Journal of Clinical Neuromuscular Disease

Volumn 2, Issue 3, 2001, Pages 129-134

  Meriggioli, Matthew N ^a,c   Barboi, Alexandru C ^a   Rowin, Julie ^a   Cochran, Elizabeth J ^b  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0037811645     PISSN: 15220443     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131402-200103000-00003     Document Type: Article

References (17)

1. London SF, Gross KF, Ringel SP. Cholesterol-lowering agent myopathy (CLAM). Neurology 1991;41:1159-1160.
2. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
3. Dalakas MC. Inflammatory and toxic myopathies. Curr Opin Neurol Neurosurg 1992;5:645-654.
4. Sinzinger H, Schmid P, O'Grady J. Two different types of exercise induced pain without myopathy and CK-elevation during HMG CoA reductase inhibitor treatment. J Neurol Sci 1999;143: 459-460.
5. Waclawik AJ, Lindal S, Engel AG. Experimental lovastatin myopathy. J Neuropathol Exp Neurol 1993;52:542-549.
6. Flint OP, Masters BA, Gregg RE, et al. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 1997;145:91-98.
7. Victor M, Sieb JP. Myopathies due to drugs, toxins and nutritional deficiency. In: Engel AG, Franzini-Armstrong C, eds. Myology, 2nd ed. New York, NY: McGraw-Hill, 1994:1697-1724.
8. East C, Grundy SM, Jones PH, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988;318:47-48.
9. Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999;22:295-297.
10. Pierce LR, Wysocki DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination. JAMA 1990;264:71-75.
11. Van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, et al. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil. J Intern Med 1996;240: 403-404.
12. Giordano N, Senesi M, Mattii G, et al. Polymyositis associated with simvastatin. Lancet 1997;349:1600-1601.
13. Pierno S, De Luca A, Liantonio A, et al. Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle. Eur J Pharmacol 1999;364:43-48.
14. Sonoda Y, Gotow T, Kuriyama M, et al. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve 1994;17:891-897.
15. Johnson JE, Zimmerman ML, Daleke DL, et al. Lipid structure and not membrane structure is the major determinant in the regulation of protein kinase C by phosphatidylserine. Biochemistry 1998;37:12020-12025.
16. De Luca A, Tricarico D, Pierno S, et al. Aging and chloride channel regulation in rat fast-twitch muscle fibers. Pflugers Arch 1994;427:80-85.
17. Breil M, Chariot P. Muscle disorders associated with cyclosporine treatment. Muscle Nerve 1999;22:1631-1636.